The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $104.63 up 3.20% from its previous closing price of $101.39. In other words, the price has increased by $3.20 from its previous closing price. On the day, 1.33 million shares were traded. RYTM stock price reached its highest trading level at $105.76 during the session, while it also had its lowest trading level at $101.22.
Ratios:
For a deeper understanding of Rhythm Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.53 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 1.75 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on November 25, 2025, initiated with a Buy rating and assigned the stock a target price of $136.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $97.Goldman initiated its Buy rating on July 10, 2025, with a $97 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 20 ’25 when Cramer Pamela J. sold 3,350 shares for $105.00 per share. The transaction valued at 351,750 led to the insider holds 20,814 shares of the business.
PAMELA CRAMER bought 3,350 shares of RYTM for $345,552 on Nov 20 ’25. On Nov 07 ’25, another insider, Cramer Pamela J., who serves as the Chief Human Resources Officer of the company, sold 19,351 shares for $98.82 each. As a result, the insider received 1,912,326 and left with 20,814 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 6982593536 and an Enterprise Value of 6826511360. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.05 while its Price-to-Book (P/B) ratio in mrq is 46.88. Its current Enterprise Value per Revenue stands at 39.158 whereas that against EBITDA is -36.948.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.01, which has changed by 0.7535455 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $116.00, while it has fallen to a 52-week low of $45.90. The 50-Day Moving Average of the stock is 0.63%, while the 200-Day Moving Average is calculated to be 30.96%.
Shares Statistics:
For the past three months, RYTM has traded an average of 647.29K shares per day and 681230 over the past ten days. A total of 66.68M shares are outstanding, with a floating share count of 62.33M. Insiders hold about 6.60% of the company’s shares, while institutions hold 106.28% stake in the company. Shares short for RYTM as of 1763078400 were 5502046 with a Short Ratio of 8.50, compared to 1760486400 on 5574246. Therefore, it implies a Short% of Shares Outstanding of 5502046 and a Short% of Float of 10.560001.
Earnings Estimates
The stock of Rhythm Pharmaceuticals Inc (RYTM) is currently being evaluated by 11.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.36 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$2.22 and -$3.34 for the fiscal current year, implying an average EPS of -$3.05. EPS for the following year is -$2.39, with 11.0 analysts recommending between -$0.7 and -$3.65.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $55.26M this quarter.It ranges from a high estimate of $57.5M to a low estimate of $52M. As of. The current estimate, Rhythm Pharmaceuticals Inc’s year-ago sales were $41.83MFor the next quarter, 14 analysts are estimating revenue of $57.92M. There is a high estimate of $61.9M for the next quarter, whereas the lowest estimate is $50M.
A total of 15 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $192.55M, while the lowest revenue estimate was $185M, resulting in an average revenue estimate of $187.97M. In the same quarter a year ago, actual revenue was $130.13MBased on 15 analysts’ estimates, the company’s revenue will be $295.44M in the next fiscal year. The high estimate is $360.7M and the low estimate is $263M.
